Dr. Schaeffer on the importance of a multidisciplinary approach when using PSMA agents
"Like any test, it's really a very powerful tool. It's just how you deploy the tool," says Edward M. Schaeffer, MD, PhD.
In this video, Edward M. Schaeffer, MD, PhD, discusses the importance of a multidisciplinary approach for using PSMA-PET agents in prostate cancer. Schaeffer is chair and Harold Binstein Professor of Urology at Northwestern University Feinberg School of Medicine in Chicago, Illinois.
Transcription:
Please discuss the importance of a multidisciplinary approach when working with PSMA PET scans.
Like any test, it's really a very powerful tool. It's just how you deploy the tool. [One factor is] how you create the tool. Is the PET PSMA agent made in-house or made with a commercial enterprise? When you actually administer the test, what is the quality of the scanner that you have that actually registers the results? And most importantly, what is the quality and the experience of the nuclear medicine physician radiologist reading the results, and then also the clinician who can actually put the whole story together and piece together what would be a potentially a positive or a negative PET scan with the clinical scenario for the patient. And so really, that requires a lot of different disciplines within a medical enterprise. And it's not just physicians, but it's actually teams of individuals, technologists, the actual imaging platforms etc.
This transcription was edited for clarity.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
